Roth Capital raised the firm’s price target on iRadimed (IRMD) to $98 from $90 and keeps a Buy rating on the shares after its Q3 earnings beat. Legacy pump sales remain strong despite the planned full launch of the next generation version in Q1, monitor sales accelerated in the quarter, and there could be nice uplift from the cross-selling the next gen pump into non-user hospitals, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRMD: